CD274 and cancer: For instance, the interaction between programmed cell death protein (PD‐1) and its ligand programmed death‐ligand (PD‐L1) could assist the immune surveillance escape, thereby promoting cancer progression.[3] Targeting PD‐1/PD‐L1 pathway using the inhibitors such as nivolumab[4] and cemiplimab[5] have been shown to be beneficial for some patients by activating the immune system.